Cancer Treatment
-
Avenda’s Platform for Personalized Prostate Cancer Mapping Earns FDA Clearance
Avenda Health, a startup focused on personalized prostate cancer care, recently received 510(k) clearance from the FDA for its cancer mapping platform. The platform uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins.
-
MedCity Influencers, BioPharma
5 years after FDA approval, CAR-T treatment looks like the future of medicine
CAR-T has become increasingly recognized as an exciting and potentially paradigm-shifting treatment in the past five years. In fact, more than 10,000 patients have undergone this new treatment for certain types of leukemia, lymphoma
and multiple myeloma. -
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
MedCity Influencers, BioPharma
Are metabolic hormones the next frontier in cancer treatment?
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
-
Wireless injectable computer could deliver more accurate reading of tumor pressure
Engineering researchers at the University of Michigan have developed a battery-operated injectable computer with a radio antenna that can transmit data to a device located up to 12 inches outside of the body.
-
Will CAR-T deliver on the promise of widespread therapeutic improvement?
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
-
ASCO: Newly approved drug for renal cell carcinoma lowers death rate
Patients with previously treated advanced renal cell carcinoma have a new treatment option with cabozantinib — a kinase inhibitor shown to improve overall survival compared to everolimus, as a Cleveland Clinic researcher noted at ASCO 2016 over the weekend.
-
Gilead Sciences holding off on six trials for its cancer drug Zydelig due to concerns of adverse effects and deaths
The FDA issued an alert about the drug on Monday, and in the warning it warned healthcare professionals that the drug is not approved for previously untreated chronic lymphocytic leukemia.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Onxeo announces acquisition of DNA Therapeutics to further develop its cancer treatment options
Under the terms of the agreement, Onxeo is acquiring DNA Therapeutics for an upfront payment of nearly $1.85 million in common shares at deal closing.
-
Medtronic acquires tech from Baylis Medical for its FDA approved OsteoCool spine cancer device
Medtronic takes over the OsteoCool device for treating cancers that metastasize to the spine, created by Baylis Medical.
-
C4 Therapeutics launches with $73M Series A for new cancer treatment approach
The startup created from Dana-Farber Cancer Institute announced today the closing of a $73 million Series A round of financing and a promising partnership with Roche.
-
GSK and Merck joining forces for potential cancer treatment
Patients who have recurrent or metastatic solid tumors that are not responding to standard treatment could soon receive helpful treatment with the help of a GSK and Merck joined effort.